메뉴 건너뛰기




Volumn 21, Issue 2, 2015, Pages 365-372

Identification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of pazopanib

(21)  Maitland, Michael L a   Xu, Chun Fang b   Cheng, Yu Ching c   Kistner Griffin, Emily g   Ryan, Kathleen A c   Karrison, Theodore G a   Das, Soma a   Torgerson, Dara h   Gamazon, Eric R a   Thomeas, Vasiliki a   Levine, Matthew R a   Wilson, Paul A d   Bing, Nan e   Liu, Yuan e   Cardon, Lon R e   Pandite, Lini N e   O'Connell, Jeffrey R c   Cox, Nancy J a   Mitchell, Braxton D c   Ratain, Mark J a   more..


Author keywords

[No Author keywords available]

Indexed keywords

PAZOPANIB; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR; PYRIMIDINE DERIVATIVE; SULFONAMIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2, HUMAN;

EID: 84921033632     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1683     Document Type: Article
Times cited : (21)

References (41)
  • 1
    • 2642570170 scopus 로고    scopus 로고
    • Moving towards individualized medicine with pharmacogenomics
    • Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature 2004;429:464-8.
    • (2004) Nature , vol.429 , pp. 464-468
    • Evans, W.E.1    Relling, M.V.2
  • 2
    • 0034660560 scopus 로고    scopus 로고
    • Pharmacogenetics and the practice of medicine
    • Roses AD. Pharmacogenetics and the practice of medicine. Nature 2000;405:857-65.
    • (2000) Nature , vol.405 , pp. 857-865
    • Roses, A.D.1
  • 3
    • 84894487280 scopus 로고    scopus 로고
    • Clinical implementation of germ line cancer pharmacogenetic variants during the next-generation sequencing era
    • Gillis NK, Patel JN, Innocenti F. Clinical implementation of germ line cancer pharmacogenetic variants during the next-generation sequencing era. Clin Pharmacol Ther 2014;95:269-80.
    • (2014) Clin Pharmacol Ther , vol.95 , pp. 269-280
    • Gillis, N.K.1    Patel, J.N.2    Innocenti, F.3
  • 5
    • 84880557325 scopus 로고    scopus 로고
    • Genomic medicine: A decade of successes, challenges, and opportunities
    • McCarthy JJ, McLeod HL, Ginsburg GS. Genomic medicine: a decade of successes, challenges, and opportunities. Sci Translational Med 2013;5: 189-4.
    • (2013) Sci Translational Med , vol.5 , pp. 189-194
    • McCarthy, J.J.1    McLeod, H.L.2    Ginsburg, G.S.3
  • 6
    • 53249118974 scopus 로고    scopus 로고
    • Pharmacogenetics in drug discovery and development: A translational perspective
    • Roses AD. Pharmacogenetics in drug discovery and development: a translational perspective. Nat Rev Drug Discov 2008;7:807-17.
    • (2008) Nat Rev Drug Discov , vol.7 , pp. 807-817
    • Roses, A.D.1
  • 7
    • 79551604866 scopus 로고    scopus 로고
    • Pharmacogenetics of endocrine therapy for breast cancer
    • Higgins MJ, Stearns V. Pharmacogenetics of endocrine therapy for breast cancer. Annu Rev Med 2011;62:281-93.
    • (2011) Annu Rev Med , vol.62 , pp. 281-293
    • Higgins, M.J.1    Stearns, V.2
  • 8
    • 58849149494 scopus 로고    scopus 로고
    • Pharmacogenetics and pharmacogenomics of anticancer agents
    • Huang RS, Ratain MJ. Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin 2009;59:42-55.
    • (2009) CA Cancer J Clin , vol.59 , pp. 42-55
    • Huang, R.S.1    Ratain, M.J.2
  • 9
    • 33745876823 scopus 로고    scopus 로고
    • TPMT, UGT1A1 and DPYD: Genotyping to ensure safer cancer therapy?
    • Maitland ML, Vasisht K, Ratain MJ. TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy? Trends Pharmacol Sci 2006;27:432-7.
    • (2006) Trends Pharmacol Sci , vol.27 , pp. 432-437
    • Maitland, M.L.1    Vasisht, K.2    Ratain, M.J.3
  • 11
    • 47949089077 scopus 로고    scopus 로고
    • VEGF-targeted therapy: Mechanisms of anti-tumour activity
    • Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008;8:579-91.
    • (2008) Nat Rev Cancer , vol.8 , pp. 579-591
    • Ellis, L.M.1    Hicklin, D.J.2
  • 12
    • 78649537524 scopus 로고    scopus 로고
    • Biomarkers to predict the clinical efficacy of bevacizumab in cancer
    • Jubb AM, Harris AL. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 2010;11:1172-83.
    • (2010) Lancet Oncol , vol.11 , pp. 1172-1183
    • Jubb, A.M.1    Harris, A.L.2
  • 13
    • 77949890945 scopus 로고    scopus 로고
    • Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial
    • Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28:1061-8.
    • (2010) J Clin Oncol , vol.28 , pp. 1061-1068
    • Sternberg, C.N.1    Davis, I.D.2    Mardiak, J.3    Szczylik, C.4    Lee, E.5    Wagstaff, J.6
  • 14
    • 84861098484 scopus 로고    scopus 로고
    • Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial
    • van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379: 1879-86.
    • (2012) Lancet , vol.379 , pp. 1879-1886
    • Van Der Graaf, W.T.1    Blay, J.Y.2    Chawla, S.P.3    Kim, D.W.4    Bui-Nguyen, B.5    Casali, P.G.6
  • 15
    • 0027249239 scopus 로고
    • Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium
    • Quinn TP, Peters KG, De Vries C, Ferrara N, Williams LT. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc Natl Acad Sci U S A 1993;90: 7533-7.
    • (1993) Proc Natl Acad Sci U S A , vol.90 , pp. 7533-7537
    • Quinn, T.P.1    Peters, K.G.2    De Vries, C.3    Ferrara, N.4    Williams, L.T.5
  • 17
    • 69949160832 scopus 로고    scopus 로고
    • Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth
    • Albuquerque RJ, Hayashi T, Cho WG, Kleinman ME, Dridi S, Takeda A, et al. Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nat Med 2009;15:1023-30.
    • (2009) Nat Med , vol.15 , pp. 1023-1030
    • Albuquerque, R.J.1    Hayashi, T.2    Cho, W.G.3    Kleinman, M.E.4    Dridi, S.5    Takeda, A.6
  • 18
    • 77957366667 scopus 로고    scopus 로고
    • Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer
    • Bass MB, Sherman SI, Schlumberger MJ, Davis MT, Kivman L, Khoo HM, et al. Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer. J Clin Endocrinol Metab 2010;95:5018-27.
    • (2010) J Clin Endocrinol Metab , vol.95 , pp. 5018-5027
    • Bass, M.B.1    Sherman, S.I.2    Schlumberger, M.J.3    Davis, M.T.4    Kivman, L.5    Khoo, H.M.6
  • 19
    • 50649095801 scopus 로고    scopus 로고
    • Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study
    • Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008;26: 4708-13.
    • (2008) J Clin Oncol , vol.26 , pp. 4708-4713
    • Cohen, E.E.1    Rosen, L.S.2    Vokes, E.E.3    Kies, M.S.4    Forastiere, A.A.5    Worden, F.P.6
  • 20
    • 33644833910 scopus 로고    scopus 로고
    • Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
    • Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24.
    • (2006) J Clin Oncol , vol.24 , pp. 16-24
    • Motzer, R.J.1    Michaelson, M.D.2    Redman, B.G.3    Hudes, G.R.4    Wilding, G.5    Figlin, R.A.6
  • 21
    • 77957570088 scopus 로고    scopus 로고
    • Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III treatment approaches in renal cancer global evaluation trial
    • Pena C, Lathia C, Shan M, Escudier B, Bukowski RM. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from sorafenib phase III treatment approaches in renal cancer global evaluation trial. Clin Cancer Res 2011;16:4853-63.
    • (2011) Clin Cancer Res , vol.16 , pp. 4853-4863
    • Pena, C.1    Lathia, C.2    Shan, M.3    Escudier, B.4    Bukowski, R.M.5
  • 22
    • 36749052895 scopus 로고    scopus 로고
    • Multiple circulating proangiogenic factors induced by sunitinib malate are tumor- independent and correlate with antitumor efficacy
    • Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor- independent and correlate with antitumor efficacy. Proc Natl Acad Sci US A 2007;104:17069-74.
    • (2007) Proc Natl Acad Sci USA , vol.104 , pp. 17069-17074
    • Ebos, J.M.1    Lee, C.R.2    Christensen, J.G.3    Mutsaers, A.J.4    Kerbel, R.S.5
  • 23
    • 77950243445 scopus 로고    scopus 로고
    • Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib
    • Nikolinakos PG, Altorki N, Yankelevitz D, Tran HT, Yan S, Rajagopalan D, et al. Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib. Cancer Res 2010;70:2171-9.
    • (2010) Cancer Res , vol.70 , pp. 2171-2179
    • Nikolinakos, P.G.1    Altorki, N.2    Yankelevitz, D.3    Tran, H.T.4    Yan, S.5    Rajagopalan, D.6
  • 24
    • 77449130846 scopus 로고    scopus 로고
    • Genome-wide association scan identifies variants near Matrix Metalloproteinase (MMP) genes on chromosome 11q21-22 strongly associated with serum MMP-1 levels
    • Cheng YC, Kao WH, Mitchell BD, O'Connell JR, Shen H, McArdle PF, et al. Genome-wide association scan identifies variants near Matrix Metalloproteinase (MMP) genes on chromosome 11q21-22 strongly associated with serum MMP-1 levels. Circ Cardiovasc Genet 2009;2: 329-37.
    • (2009) Circ Cardiovasc Genet , vol.2 , pp. 329-337
    • Cheng, Y.C.1    Kao, W.H.2    Mitchell, B.D.3    O'Connell, J.R.4    Shen, H.5    McArdle, P.F.6
  • 25
    • 42649109683 scopus 로고    scopus 로고
    • The genetic response to short-term interventions affecting cardiovascular function: Rationale and design of theHeredity and Phenotype Intervention (HAPI) Heart Study
    • Mitchell BD, McArdle PF, Shen H, Rampersaud E, Pollin TI, Bielak LF, et al. The genetic response to short-term interventions affecting cardiovascular function: rationale and design of theHeredity and Phenotype Intervention (HAPI) Heart Study. Am Heart J 2008;155:823-8.
    • (2008) Am Heart J , vol.155 , pp. 823-828
    • Mitchell, B.D.1    McArdle, P.F.2    Shen, H.3    Rampersaud, E.4    Pollin, T.I.5    Bielak, L.F.6
  • 26
    • 70349696526 scopus 로고    scopus 로고
    • Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment
    • Maitland ML, Kasza KE, Karrison T, Moshier K, Sit L, Black HR, et al. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res 2009;15:6250-7.
    • (2009) Clin Cancer Res , vol.15 , pp. 6250-6257
    • Maitland, M.L.1    Kasza, K.E.2    Karrison, T.3    Moshier, K.4    Sit, L.5    Black, H.R.6
  • 27
    • 84891550456 scopus 로고    scopus 로고
    • Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer
    • Maitland ML, Levine MR, Lacouture ME, Wroblewski KE, Chung CH, Gordon IO, et al. Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer. BMC Cancer 2014;14:5.
    • (2014) BMC Cancer , vol.14 , pp. 5
    • Maitland, M.L.1    Levine, M.R.2    Lacouture, M.E.3    Wroblewski, K.E.4    Chung, C.H.5    Gordon, I.O.6
  • 28
    • 84902783979 scopus 로고    scopus 로고
    • Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies
    • Karovic S, Wen Y, Karrison TG, Bakris GL, Levine MR, House LK, et al. Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies. Clin Pharmacol Ther 2014;96:27-35.
    • (2014) Clin Pharmacol Ther , vol.96 , pp. 27-35
    • Karovic, S.1    Wen, Y.2    Karrison, T.G.3    Bakris, G.L.4    Levine, M.R.5    House, L.K.6
  • 29
    • 55349124241 scopus 로고    scopus 로고
    • Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor
    • ASCO Meeting Abstracts
    • Hutson TE, Davis ID, Machiels JH, de Souza PL, Baker K, Bordogna W, et al. Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor. ASCO Meeting Abstracts. J Clin Oncol 2008;26s:5046.
    • (2008) J Clin Oncol , vol.26 S , pp. 5046
    • Hutson, T.E.1    Davis, I.D.2    Machiels, J.H.3    De Souza, P.L.4    Baker, K.5    Bordogna, W.6
  • 30
    • 56349155783 scopus 로고    scopus 로고
    • Concept, design and implementation of a cardiovascular gene-centric 50 k SNP array for large-scale genomic association studies
    • Keating BJ, Tischfield S, Murray SS, Bhangale T, Price TS, Glessner JT, et al. Concept, design and implementation of a cardiovascular gene-centric 50 k SNP array for large-scale genomic association studies. PLoS ONE 2008;3: e3583.
    • (2008) PLoS ONE , vol.3 , pp. e3583
    • Keating, B.J.1    Tischfield, S.2    Murray, S.S.3    Bhangale, T.4    Price, T.S.5    Glessner, J.T.6
  • 33
    • 84899828567 scopus 로고    scopus 로고
    • Technical considerations in the development of circulating peptides as pharmacodynamic biomarkers for angiogenesis inhibitors
    • Thomeas V, Chow S, Gutierrez JO, Karovic S, Wroblewski K, Kistner-Griffin E, et al. Technical considerations in the development of circulating peptides as pharmacodynamic biomarkers for angiogenesis inhibitors. J Clin Pharmacol 2014;54:682-7.
    • (2014) J Clin Pharmacol , vol.54 , pp. 682-687
    • Thomeas, V.1    Chow, S.2    Gutierrez, J.O.3    Karovic, S.4    Wroblewski, K.5    Kistner-Griffin, E.6
  • 34
    • 58149262866 scopus 로고    scopus 로고
    • A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection
    • Pollin TI, Damcott CM, Shen H, Ott SH, Shelton J, Horenstein RB, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 2008;322:1702-5.
    • (2008) Science , vol.322 , pp. 1702-1705
    • Pollin, T.I.1    Damcott, C.M.2    Shen, H.3    Ott, S.H.4    Shelton, J.5    Horenstein, R.B.6
  • 37
    • 80051705165 scopus 로고    scopus 로고
    • Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer
    • Glubb DM, Cerri E, Giese A, Zhang W, Mirza O, Thompson EE, et al. Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer. Clin Cancer Res 2011;17:5257-67.
    • (2011) Clin Cancer Res , vol.17 , pp. 5257-5267
    • Glubb, D.M.1    Cerri, E.2    Giese, A.3    Zhang, W.4    Mirza, O.5    Thompson, E.E.6
  • 38
    • 0004283299 scopus 로고
    • Chromosome variability and geographic distribution in insects
    • John B, Lewis KR. Chromosome variability and geographic distribution in insects. Science 1966;152:711-21.
    • (1966) Science , vol.152 , pp. 711-721
    • John, B.1    Lewis, K.R.2
  • 39
    • 0038823525 scopus 로고    scopus 로고
    • The endophenotype concept in psychiatry: Etymology and strategic intentions
    • Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003;160:636-45.
    • (2003) Am J Psychiatry , vol.160 , pp. 636-645
    • Gottesman, I.I.1    Gould, T.D.2
  • 40
    • 55549090302 scopus 로고    scopus 로고
    • Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma
    • Jinnin M, Medici D, Park L, Limaye N, Liu Y, Boscolo E, et al. Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma. Nat Med 2008;14:1236-46.
    • (2008) Nat Med , vol.14 , pp. 1236-1246
    • Jinnin, M.1    Medici, D.2    Park, L.3    Limaye, N.4    Liu, Y.5    Boscolo, E.6
  • 41
    • 0032553425 scopus 로고    scopus 로고
    • Mapping of the sites involved in ligand association and dissociation at the extracellular domain of the kinase insert domain-containing receptor for vascular endothelial growth factor
    • Shinkai A, Ito M, Anazawa H, Yamaguchi S, Shitara K, Shibuya M. Mapping of the sites involved in ligand association and dissociation at the extracellular domain of the kinase insert domain-containing receptor for vascular endothelial growth factor. J Biol Chem 1998;273:31283-8.
    • (1998) J Biol Chem , vol.273 , pp. 31283-31288
    • Shinkai, A.1    Ito, M.2    Anazawa, H.3    Yamaguchi, S.4    Shitara, K.5    Shibuya, M.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.